Tae Keun Oh

Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial

Hiddo J.L. Heerspink, Hans‐Henrik Parving, Dennis L. Andress et al. · The Lancet · 2019 · 612 citations · Full text

Medicine, Endocrinology, Nephrology +10

Empagliflozin versus dapagliflozin in patients with type 2 diabetes inadequately controlled with metformin, glimepiride and dipeptidyl peptide 4 inhibitors: A 52-week prospective observational study

Eu Jeong Ku, Dong‐Hwa Lee, Hyun Jeong Jeon et al. · Diabetes Research and Clinical Practice · 2019 · 64 citations

Medicine, Pharmacology, Pharmacotherapy +13

Comparison of Vildagliptin-Metformin and Glimepiride-Metformin Treatments in Type 2 Diabetic Patients

Hyun Jeong Jeon, Tae Keun Oh · Diabetes & Metabolism Journal · 2011 · 45 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Long-term effectiveness and safety of quadruple combination therapy with empagliflozin versus dapagliflozin in patients with type 2 diabetes: 3-year prospective observational study

Eu Jeong Ku, Dong‐Hwa Lee, Hyun Jeong Jeon et al. · Diabetes Research and Clinical Practice · 2021 · 32 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Effectiveness and safety of empagliflozin‐based quadruple therapy compared with insulin glargine‐based therapy in patients with inadequately controlled type 2 diabetes: An observational study in clinical practice

Eu Jeong Ku, Dong‐Hwa Lee, Hyun Jeong Jeon et al. · Diabetes Obesity and Metabolism · 2018 · 27 citations · Full text

Medicine, Endocrinology, Pharmacology +17